Michelle E. Melisko


Breast oncologist

About me

Dr. Michelle E. Melisko is a cancer specialist with expertise in caring for patients with breast cancer.

Also active in research, Melisko is interested in evaluating new chemotherapy combinations, biological therapies and immunotherapies for breast cancer, with a particular focus on treating cancer that has spread to the brain. To foster more rapid advances in breast cancer treatment, she educates patients on clinical trials and encourages them to participate when appropriate.

Melisko earned her medical degree at the Wake Forest School of Medicine and completed a residency in internal medicine at Stanford Medicine. She completed a fellowship in hematology and oncology at UCSF.

  • Education

    Wake Forest University School of Medicine, 1997

  • Residencies

    Stanford Hospital and Clinics, Internal Medicine, 2000

  • Fellowships

    UCSF Medical Center, Hematology/Oncology, 2003

  • Board Certifications

    Hospice & Palliative Medicine, American Board of Internal Medicine

  • Academic Title


Carol Franc Buck Breast Care Center

Bakar Precision Cancer Medicine Building

1825 Fourth St., Third Floor
San Francisco, CA 94158

Decorative Caduceus

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

To evaluate the objective response rate in the Central Nervous System by composite response criteria in Cohort 1


Decorative Caduceus

Oral Paclitaxel Efficacy Safety and PK in Recurrent and Metastatic Breast Cancer

ORR is defined by Response Evaluation Criteria in Solid Tumors (RECIST) (v.1.1) criteria


Decorative Caduceus

Neratinib HER Mutation Basket Study (SUMMIT)

Confirmed objective response rate following treatment with neratinib in patients with HER2 (ERBB2), HER3 (ERBB3) or EGFR mutation-positive solid tumors or with EGFR gene amplification.